Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:SIGA NASDAQ:SLDB NASDAQ:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.86$2.71$1.92▼$3.43$1.07B0.891.06 million shs1.08 million shsSIGASiga Technologies$3.86$4.39$3.56▼$9.62$276.86M0.96563,846 shs544,961 shsSLDBSolid Biosciences$10.84$7.57$3.79▼$10.88$1.07B2.362.69 million shs2.63 million shsVORVor Biopharma$20.59$15.04$6.50▼$65.80$1.12B1.691.47 million shs3.91 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%+4.76%+4.76%+13.04%+43.00%SIGASiga Technologies+3.76%-2.28%-10.65%-26.34%-42.22%SLDBSolid Biosciences+6.27%+22.35%+64.74%+44.73%+122.59%VORVor Biopharma+11.96%+37.91%+50.73%+14.07%-29.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.86$2.71$1.92▼$3.43$1.07B0.891.06 million shs1.08 million shsSIGASiga Technologies$3.86$4.39$3.56▼$9.62$276.86M0.96563,846 shs544,961 shsSLDBSolid Biosciences$10.84$7.57$3.79▼$10.88$1.07B2.362.69 million shs2.63 million shsVORVor Biopharma$20.59$15.04$6.50▼$65.80$1.12B1.691.47 million shs3.91 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%+4.76%+4.76%+13.04%+43.00%SIGASiga Technologies+3.76%-2.28%-10.65%-26.34%-42.22%SLDBSolid Biosciences+6.27%+22.35%+64.74%+44.73%+122.59%VORVor Biopharma+11.96%+37.91%+50.73%+14.07%-29.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 2.20Hold$2.30-19.58% DownsideSIGASiga Technologies 1.00SellN/AN/ASLDBSolid Biosciences 2.92Moderate Buy$17.0056.83% UpsideVORVor Biopharma 2.82Moderate Buy$42.25105.20% UpsideCurrent Analyst Ratings BreakdownLatest SIGA, CRON, VOR, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/30/2026VORVor Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/15/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/15/2026VORVor Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026SLDBSolid Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.006/1/2026VORVor Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/28/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/18/2026VORVor Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/14/2026VORVor Biopharma WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$15.00 ➝ $18.005/13/2026SLDBSolid Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$17.00 ➝ $18.00(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$146.59M7.28$0.01 per share228.13$3.00 per share0.95SIGASiga Technologies$93.78M2.95$0.35 per share11.17$2.78 per share1.39SLDBSolid BiosciencesN/AN/AN/AN/A$2.28 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$9.45M$0.01286.29N/AN/A-1.14%-1.26%-1.20%8/6/2026 (Estimated)SIGASiga Technologies$23.28M$0.2714.30N/AN/A21.58%10.60%8.94%8/4/2026 (Estimated)SLDBSolid Biosciences-$174.32M-$1.95N/AN/AN/AN/A-73.42%-61.13%8/11/2026 (Estimated)VORVor BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest SIGA, CRON, VOR, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLDBSolid Biosciences-$0.40-$0.52-$0.12-$0.52N/AN/A5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$45.21 million5/7/2026Q1 2026SIGASiga TechnologiesN/A-$0.05N/A-$0.05N/A$6.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A21.8720.73SIGASiga TechnologiesN/A3.252.38SLDBSolid BiosciencesN/A13.1013.10VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%SIGASiga Technologies55.40%SLDBSolid Biosciences81.46%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipCRONCronos Group7.80%SIGASiga Technologies2.73%SLDBSolid Biosciences2.66%VORVor Biopharma0.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450373.03 million343.94 millionOptionableSIGASiga Technologies4071.72 million69.77 millionOptionableSLDBSolid Biosciences10098.45 million95.83 millionOptionableVORVor Biopharma14054.19 million54.04 millionN/ASIGA, CRON, VOR, and SLDB HeadlinesRecent News About These CompaniesVor Biopharma Stock Short Interest Report | NASDAQ:VOR | Benzinga4 hours ago | benzinga.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 2 at 5:30 PM | globenewswire.comWhy Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's NextJune 30 at 3:27 PM | finance.yahoo.comVor Biopharma (NASDAQ:VOR) Trading 8% Higher - Still a Buy?June 28, 2026 | americanbankingnews.comVor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaJune 8, 2026 | finanznachrichten.deTelitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in ChinaJune 8, 2026 | globenewswire.comTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaJune 8, 2026 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comVor Bio to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comWe're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash WiselyMay 15, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Protara Therapeutics (TARA), Vor Biopharma (VOR)May 14, 2026 | theglobeandmail.comVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineMay 14, 2026 | globenewswire.comVor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | finanznachrichten.deVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comWall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to TradeMay 7, 2026 | zacks.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comVor Biopharma (NASDAQ:VOR) Director Sells $2,711,856.51 in StockApril 22, 2026 | insidertrades.comDoes Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?April 20, 2026 | zacks.comRa Capital Management, L.P. Sells 53,644 Shares of Vor Biopharma (NASDAQ:VOR) StockApril 16, 2026 | insidertrades.comRa Capital Management, L.P. Sells 828 Shares of Vor Biopharma (NASDAQ:VOR) StockApril 11, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMicron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Apple Just Handed These 4 Memory Stocks Their Best News of the YearBy Bridget Bennett | June 28, 2026SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right NowBy Bridget Bennett | June 28, 2026Micron’s HBM Surge Could Redefine the AI Growth StoryBy Thomas Hughes | June 25, 2026Is the Memory Rally Still Alive After the Semiconductor Sell-Off?By Jessica Mitacek | July 2, 2026SIGA, CRON, VOR, and SLDB Company DescriptionsCronos Group NASDAQ:CRON$2.86 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.88 +0.02 (+0.52%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Siga Technologies NASDAQ:SIGA$3.86 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.04 +0.19 (+4.79%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Solid Biosciences NASDAQ:SLDB$10.84 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$10.84 0.00 (-0.05%) As of 07/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Vor Biopharma NASDAQ:VOR$20.59 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$20.30 -0.29 (-1.43%) As of 07/2/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear 3 Dividend ETFs Built for Stability in a Volatile Market Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
